...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur
【24h】

Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur

机译：Nordic MCL2试验更新：对未经治疗的套细胞淋巴瘤进行强化免疫化学疗法后的六年随访，然后进行BEAM或BEAC +自体干细胞支持：存活期仍很长，但确实会出现晚期复发

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early - based on the median observation time of 4 years - results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6·5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7·4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at as ISRCTN 87866680.
机译：套细胞淋巴瘤（MCL）是异源性非霍奇金淋巴瘤实体，中位生存期约为5年。 2008年，我们报告了基于4年平均观察时间的北欧淋巴瘤小组MCL2对一线强化诱导免疫化学疗法和自体干细胞移植（ASCT）进行的研究的早期结果，该研究在5岁时无事件生存率超过60％年，并且没有随后复发的报道。在这里，我们提出了中位观察时间为6·5年后的更新。总体结果仍然非常好，中位总生存期和响应持续时间超过10年，中位无事件生存期为7·4年。但是，现在有6位患者在治疗结束后不到5年才进展。国际MCL预后指数（MIPI）和Ki-67表达是唯一独立的预后因素。根据MIPI-Biological Index（MIPI + Ki-67，MIPI-B）细分，低中级MIPI-B的患者在70岁时还活着超过70％，但高MIPI-B的患者仅占23％ 。这些结果尽管对大多数患者而言是令人鼓舞的，但强调了针对MCL的风险适应性治疗策略的需求。该研究的注册号为ISRCTN 87866680。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号